Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring - LARVOL DELTA

Real-world use of pegylated erythropoietin in CKD-related anemia: an Indian modified Delphi consensus. (PubMed, Front Nephrol) - "Methoxy polyethylene glycol epoetin beta (MPG-EPO; PegEPO), a long-acting ESA with an extended half-life, enables less frequent administration and may offer advantages in Hb stabilization, treatment adherence, and patient convenience...This modified Delphi consensus provides evidence-informed, expert-driven recommendations to support individualized and pragmatic use of PegEPO in routine clinical practice. However, these statements represent expert consensus and are not intended as clinical guidelines; therefore, they should be adapted based on individual patient context and local clinical practice."

Journal • Real-world evidence • Anemia • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Comparative efficacy and safety of methoxy polyethylene glycol-epoetin beta and roxadustat in the management of renal anemia in maintenance hemodialysis. (PubMed, Front Pharmacol) - "Hb target attainment and hypertension-rate comparisons did not show statistically significant treatment-by-time interaction effects. Because treatment allocation reflected clinical practice and patient preference, residual selection bias remains an important competing explanation."

Journal • Anemia • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Hypertension • Nephrology • Renal Disease • CRP

Comparison of Efficacy and Safety between MIRCERA and Roxadustat in the Treatment of Renal Anemia (ChiCTR) - P4 | N=60 | Completed | Sponsor: Guangdong Second Provincial General Hospital; Guangdong Second Provincial General Hospital

New P4 trial • Anemia • Hematological Disorders

Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial. (PubMed, Kidney Res Clin Pract) - "Over 12 weeks, HD patients received intravenous efepoetin alfa (5 or 8 µg/kg once weekly [Q1W], 8 µg/kg every 2 weeks [Q2W]) or darbepoetin alfa (30 µg Q1W). PD patients received subcutaneous efepoetin alfa (5 or 8 µg/kg Q2W) or methoxy polyethylene glycol-epoetin beta (0.6 µg/kg Q2W)...Exploratory DCR analysis supported 4 µg/kg Q2W efepoetin alfa as the phase 3 starting dose. Efepoetin alfa demonstrated dose-dependent erythropoietic efficacy and an acceptable safety profile in dialysis patients, supporting dose-range characterization and phase 3 starting dose selection."

Journal • P2 data • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Transformer-Based Deep Learning Model for Predicting Hemoglobin Response to Mircera® in Hemodialysis Patients. (PubMed, Blood Purif) - "Our results showed the promising performance of a transformer-based machine learning model in predicting future Hgb levels within 6% of observed levels in HD patients being treated with Mircera® and IV iron. These findings suggest the potential for personalized ESA dosing strategies informed by sequential clinical data. Future studies should focus on refining these models and evaluate their real-world clinical utility with the goal of personalized ESA dosing to maximize on-target Hgb levels."

Journal • Diabetes • Hematological Disorders • Metabolic Disorders • Renal Disease

Comparative outcomes of red blood cell transfusion versus erythropoiesis-stimulating agents in lung cancer patients with chemotherapy-induced anemia: A real-world analysis. (ASCO 2026) - "Participants were stratified by receipt of RBC transfusion or ESA therapy (epoetin alfa, darbepoetin alfa, or methoxy polyethylene glycol-epoetin beta). In this real-world analysis, ESA therapy was associated with lower risks of sepsis and myocardial infarction, but a higher incidence of brain metastases, potentially due to erythropoietin receptor-mediated tumor progression. These findings may inform individualized risk-benefit discussions when selecting anemia management strategies in lung cancer. Prospective studies are needed to validate these associations."

Clinical • Real-world • Real-world evidence • Anemia • Chemotherapy-Induced Anemia • Infectious Disease • Lung Cancer • Myocardial Infarction • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Solid Tumor

Dialysis-Assisted Phlebotomy: A Therapeutic Approach for Porphyria Cutanea Tarda (NKF-SCM 2026) - "Hemoglobin was monitored weekly; Mircera was started when Hgb fell below 10 g/dL and titrated...Neuropathy persisted but improved with low-dose gabapentin. CONCLUSION This case underscores the need for individualized PCT management in dialysis patients, balancing iron reduction with anemia correction. Dialysis-adapted phlebotomy combined with ESA support achieved biochemical and clinical improvement."

Genetic Disorders • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Neuralgia • Rare Diseases • Renal Disease

Comparative Safety of Long-Acting Versus Short-Acting Erythropoiesis-Stimulating Agents (ESA): Disproportionality Analysis Using the FDA Adverse Event Reporting System. (PubMed, J Patient Saf) - "Our analysis found disproportionately reported AEs for long-acting ESAs, particularly when ESAs were the PS, highlighting the importance of monitoring AEs not listed in the package label, such as falls. Furthermore, despite existing black box warnings regarding cardiovascular risks, our analysis found weak evidence for cardiovascular safety signals strictly attributable to long-acting ESAs. Further studies are needed to confirm the association between these signals and long-acting ESAs."

Adverse events • Journal • Back Pain • Cardiovascular • Chronic Kidney Disease • Dermatology • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Musculoskeletal Pain • Nephrology • Pain • Pruritus • Pulmonary Disease • Renal Disease • Urticaria

EFFICACY OF LONG-ACTING ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN ANEMIC CHRONIC KIDNEY DISEASE PATIENTS WITH DIABETES MELLITUS: A SUBGROUP ANALYSIS OF A PHASE 3 NON-INFERIORITY TRIAL (ISN-WCN 2026) - P3 | "Efepoetin alfa, a novel long-acting erythropoietin (EPO)-hybrid Fc fusion protein, was previously shown to be non-inferior to methoxy polyethylene glycol-epoetin beta (mPEG-epoetin beta) for the treatment of anemia in CKD in a pivotal phase 3 trial. Timothy Widjaja is a full-time employee of PT Kalbe Genexine Biologics, which is the developer and manufacturer of Efepoetin alfa. The phase 3 clinical trial mentioned in this abstract was funded by PT Kalbe Genexine Biologics.I did not use generative AI and AI-assisted technologies in the writing process."

Clinical • Head-to-Head • P3 data • Chronic Kidney Disease • Diabetes • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease

VOICE: Vafseo Outcomes In-Center Experience (clinicaltrials.gov) - P3 | N=2200 | Active, not recruiting | Sponsor: USRC Kidney Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Forecasting the Biological Effect of PEGylated-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach. (PubMed, Pharm Res) - "Middle-out modeling successfully predicted clinical performance of PEG-EPO candidates and identified 0.4 µg/kg Q2W as optimal starting dose for clinical trials. PEG-EPO 32 kDa and 40 kDa emerges as a promising candidate for further development. This study exemplifies the value of MIDD in optimizing dose selection, enhancing translational relevance, and de-risking early clinical evaluation of long-acting erythropoiesis-stimulating agents in CKD."

Journal • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis. (PubMed, BMC Nephrol) - "Daprodustat and roxadustat indicated equivalent or higher efficacy when compared to darbepoetin in elevating hemoglobin levels in CKD-related anemia, with daprodustat demonstrating a good safety profile. While conventional ESAs remain beneficial, HIF-PHIs offer promising oral alternatives with possible benefits in cardiovascular safety and decreased hypertension risk. Further head-to-head trials are necessary to confirm these findings and guide individualized treatment strategies."

Clinical • HEOR • Journal • Retrospective data • Review • Anemia • Cardiovascular • Chronic Kidney Disease • Diabetes • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Renal Disease

Simulated Effect of Continuous Erythropoietin Receptor Activator Monthly vs. Every Two-Week Dosing on Hemoglobin in Anemia Correction of Patients on Dialysis (KIDNEY WEEK 2025) - "Funding Commercial Support – Vifor Fresenius Medical Care Renal Pharma Background Methoxy polyethylene glycol epoetin beta (Continuous EPO Receptor Activator C.E.R.A.) is indicated for treatment of anemia in chronic kidney disease...Prospective trials or real-world data are needed for confirmation. Median Hb and CERA dose over time"

Clinical • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Retraining the Anemia Control Model (ACM) for the North American Dialysis Population: A Large-Scale In-Silico Trial (KIDNEY WEEK 2025) - "Our focus is on adapting the model to methoxy polyethylene glycol-epoetin beta (MPG-E), a drug more commonly used in the U.S., and revising ESA dosing strategies to reflect regional treatment targets (10–11 g/dL in the U.S. vs. 10–12 g/dL in Europe)...Retraining improved performance and preserved fairness across demographics. In-silico validation showed effective hemoglobin control and reduced ESA use."

Clinical • Anemia • Chronic Kidney Disease • Hematological Disorders

Physiology-Driven Transformer Model to Predict Hemoglobin Response and Personalize Erythropoiesis-Stimulating Agent Dosing in Hemodialysis (KIDNEY WEEK 2025) - "Clinical, dialysis, and laboratory data were structured into an event-based dataset, where each event included pre-dose Hgb, Mircera® and iron doses, and follow-up Hgb 7–21 days later...Conclusion By integrating pharmacodynamics with sequential clinical data, our transformer-based model provides a novel framework for individualized hemoglobin prediction. This approach may inform future efforts to optimize ESA dosing in hemodialysis care."

Anemia • Diabetes • Hematological Disorders • Metabolic Disorders • Renal Disease

Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - P3 | N=228 | Recruiting | Sponsor: Biocad

New P3 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Selection, characterization and the application of the RNA aptamer in the capture assay of Erythropoietin (EPO). (PubMed, Talanta) - "REPORA-6 RNA aptamer also retains its binding against degylosylated EPO and interacts with both Epoetin Beta and Mircera, suggesting that this aptamer binds to the protein domain of the recombinant EPO despite the variation in the glycosylation side chains...We have incorporated this aptamer into a capture assay and found out that the limit of detection achieved was 19.6 pM. REPORA-6b RNA has an immense potential in applications involving doping detection of EPO."

Journal

Effect of Erythropoiesis-Stimulating Agent Types on Hemoglobin Variability in Hemodialysis Patients. (PubMed, J Clin Med) - "ESAs are categorized into short-acting (epoetin alfa/beta/delta, requiring more frequent administration), intermediate-acting (darbepoetin alfa), and long-acting agents (methoxy polyethylene glycol-epoetin beta, requiring extended dosing intervals), each with distinct pharmacokinetic properties and dosing schedules. Our cohort study found that the use of short-acting ESAs showed the lowest hemoglobin variability, whereas the use of intermediate-acting ESAs showed the highest variability. In the context of South Korea's healthcare system, where frequent hemoglobin monitoring and strict ranges are emphasized, short-acting ESAs combined with regular laboratory follow-up appeared to support more stable hemoglobin levels."

Journal • Cardiovascular • Renal Disease

Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. (PubMed, Nephrology (Carlton)) - "Efepoetin alfa demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in correcting anaemia and maintaining haemoglobin (Hb) levels among stage 3 and 4 CKD patients. Moreover, the safety profile of efepoetin alfa was comparable to methoxy polyethylene glycol-epoetin beta."

Biomarker • Clinical • Head-to-Head • Journal • P3 data • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Transcriptomic Biomarkers in Blood Indicative of the Administration of Recombinant Human Erythropoietin to Thoroughbred Horses. (PubMed, Drug Test Anal) - "Machine learning of blood transcriptomes has enabled the discrimination of samples with or without Mircera administration. Therefore, our study has provided new insights into the biological mechanism of erythropoiesis caused by rhEPO administration in horses and has provided evidence supporting the control of misuse of ESAs by monitoring the equine blood transcriptome."

Biomarker • Journal

Vadadustat (Vafseo) for anemia of chronic kidney disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing (PRNewswire) - "This round of financing will support Alebund in advancing the development and commercial activities of its pipelines in renal disease and to accelerate the development of multiple clinical-stage programs. The fund will support accelerating new drug application (NDA) in China for the best-in-class iron-based phosphate binder AP301 and the conduct of its global pivotal study; the conduct of US/China phase 2 study for the first-in-class pan phosphate transporter inhibitor AP306, and further commercial expansion for Mircera in China."

Financing • Chronic Kidney Disease • Renal Disease

VOICE: Vafseo Outcomes In-Center Experience (clinicaltrials.gov) - P3 | N=2200 | Recruiting | Sponsor: USRC Kidney Research | Not yet recruiting ➔ Recruiting

Enrollment open • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Hemoglobin (hgb) Target Range Associated with All-Cause Repeated Hospitalization in Patients on Hemodialysis Treated with Mircera (KIDNEY WEEK 2024) - "Current US guidelines call for a hgb target range of 10 to 11 g/dL. In our observational research, we identified a wider and higher hgb range to be associated with lower all-cause hospitalization. Limitations of retrospective research apply."

Clinical • Anemia • Diabetes • Hematological Disorders • Metabolic Disorders

Association of Risk of Death and Hemoglobin (hgb) Variability in Anemia Management of Patients on Hemodialysis (KIDNEY WEEK 2024) - "For the current analysis we studied hgb variability in different strata of cumulatively administered long-acting ESA (Mircera). We defined the baseline period as 6 months from the first ESA dose which had to be administered within 90 days of HD initiation... Current US guidelines indicate hgb target range of 10 to 11 g/dL when treated with ESAs. Our retrospective research identified a wider and higher hgb range to be associated with lower mortality rates independent of variability. Based on the bivariate investigation, increased variability seems to confer a more accentuated risk increase at higher cumulative ESA doses."

Clinical • Anemia • Diabetes • Hematological Disorders • Metabolic Disorders